Tikomed (Sweden)

Recent papers from Tikomed (Sweden)

1. Pleiotropic Bioactivity of Caterpillar Fungus, Orange Cordyceps, and Cordycepin: Insight from Integrated Network Pharmacology and Food and Drug Regulatory FrameworkPharmaceuticals · 2026
2. A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trialPLoS ONE · 2024
3. A clinical stage LMW-DS drug inhibits infection of human cells by Dengue, Zika and Yellow Fever viruses2022
4. The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral SclerosisFrontiers in Pharmacology · 2022
5. ILB®, a Low Molecular Weight Dextran Sulphate, Restores Glutamate Homeostasis, Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain InjuryInternational Journal of Molecular Sciences · 2022
6. A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral SclerosisPLoS ONE · 2022
7. ILB® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral SclerosisJournal of Personalized Medicine · 2021
8. ILB® resolves inflammatory scarring and promotes functional tissue repairnpj Regenerative Medicine · 2021
9. Low Molecular Weight Dextran Sulfate (ILB®) Administration Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the RatAntioxidants · 2020
10. Low Molecular Weight Dextran Sulfate Is Well Tolerated in Humans and Increases Endogenous Expression of Islet Protective Hepatocyte Growth FactorTransplantation · 2008